NovoCure Limited
NVCR
$15.21
$3.2827.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.28% | 11.17% | 14.58% | 18.27% | 18.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.28% | 11.17% | 14.58% | 18.27% | 18.82% |
| Cost of Revenue | 21.29% | 15.98% | 11.78% | 7.14% | 6.77% |
| Gross Profit | 4.51% | 9.70% | 15.47% | 21.99% | 22.85% |
| SG&A Expenses | -2.57% | 15.78% | 14.62% | 11.44% | 10.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.29% | 11.79% | 9.84% | 7.16% | 5.07% |
| Operating Income | 10.12% | -14.17% | 4.78% | 20.99% | 25.92% |
| Income Before Tax | -3.88% | -31.45% | -0.66% | 24.66% | 31.59% |
| Income Tax Expenses | -100.06% | -23.08% | 4.76% | 68.16% | 144.82% |
| Earnings from Continuing Operations | 19.21% | -18.60% | -1.33% | 14.82% | 18.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.21% | -18.60% | -1.33% | 14.82% | 18.55% |
| EBIT | 10.12% | -14.17% | 4.78% | 20.99% | 25.92% |
| EBITDA | 12.82% | -13.30% | 5.68% | 22.33% | 27.16% |
| EPS Basic | 21.71% | -15.64% | 0.87% | 16.28% | 19.77% |
| Normalized Basic EPS | 1.78% | -26.87% | -1.14% | 20.03% | 26.59% |
| EPS Diluted | 21.71% | -15.64% | 0.87% | 16.28% | 19.77% |
| Normalized Diluted EPS | 1.78% | -26.87% | -1.14% | 20.03% | 26.59% |
| Average Basic Shares Outstanding | 3.32% | 2.80% | 2.30% | 1.73% | 1.40% |
| Average Diluted Shares Outstanding | 3.32% | 2.80% | 2.30% | 1.73% | 1.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |